Literature DB >> 33641046

Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision.

Manuel Weber1, Walter Jentzen2, Regina Hofferber2, Ken Herrmann2, Wolfgang Peter Fendler2, Maurizio Conti3, Axel Wetter4, David Kersting2, Christoph Rischpler2, Pedro Fragoso Costa2.   

Abstract

AIM: [68Ga]Ga-PSMA-11 PET/CT allows for a superior detection of prostate cancer tissue, especially in the context of a low tumor burden. Digital PET/CT bears the potential of reducing scan time duration/administered tracer activity due to, for instance, its higher sensitivity and improved time coincidence resolution. It might thereby expand [68Ga]Ga-PSMA-11 PET/CT that is currently limited by 68Ge/68Ga-generator yield. Our aim was to clinically evaluate the influence of a reduced scan time duration in combination with different image reconstruction algorithms on the diagnostic performance.
METHODS: Twenty prostate cancer patients (11 for biochemical recurrence, 5 for initial staging, 4 for metastatic disease) sequentially underwent [68Ga]Ga-PSMA-11 PET/CT on a digital Siemens Biograph Vision. PET data were collected in continuous-bed-motion mode with a mean scan time duration of 16.7 min (reference acquisition protocol) and 4.6 min (reduced acquisition protocol). Four iterative reconstruction algorithms were applied using a time-of-flight (TOF) approach alone or combined with point-spread-function (PSF) correction, each with 2 or 4 iterations. To evaluate the diagnostic performance, the following metrics were chosen: (a) per-region detectability, (b) the tumor maximum and peak standardized uptake values (SUVmax and SUVpeak), and (c) image noise using the liver's activity distribution.
RESULTS: Overall, 98% of regions (91% of affected regions) were correctly classified in the reduced acquisition protocol independent of the image reconstruction algorithm. Two nodal lesions (each ≤ 4 mm) were not identified (leading to downstaging in 1/20 cases). Mean absolute percentage deviation of SUVmax (SUVpeak) was approximately 9% (6%) for each reconstruction algorithm. The mean image noise increased from 13 to 21% (4 iterations) and from 10 to 15% (2 iterations) for PSF + TOF and TOF images.
CONCLUSIONS: High agreement at 3.5-fold reduction of scan time in terms of per-region detection (98% of regions) and image quantification (mean deviation ≤ 10%) was demonstrated; however, small lesions can be missed in about 10% of patients leading to downstaging (T1N0M0 instead of T1N1M0) in 5% of patients. Our results suggest that a reduction of scan time duration or administered [68Ga]Ga-PSMA-11 activities can be considered in metastatic patients, where missing small lesions would not impact patient management. Limitations include the small and heterogeneous sample size and the lack of follow-up.

Entities:  

Keywords:  Image quality; PET/CT; PSMA; Silicon photomultiplier

Year:  2021        PMID: 33641046      PMCID: PMC7914332          DOI: 10.1186/s13550-021-00765-y

Source DB:  PubMed          Journal:  EJNMMI Res        ISSN: 2191-219X            Impact factor:   3.138


  23 in total

1.  Ultra-low-dose PET reconstruction using generative adversarial network with feature matching and task-specific perceptual loss.

Authors:  Jiahong Ouyang; Kevin T Chen; Enhao Gong; John Pauly; Greg Zaharchuk
Journal:  Med Phys       Date:  2019-06-17       Impact factor: 4.071

2.  68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study.

Authors:  Wolfgang Peter Fendler; Jeremie Calais; Martin Allen-Auerbach; Christina Bluemel; Nina Eberhardt; Louise Emmett; Pawan Gupta; Markus Hartenbach; Thomas A Hope; Shozo Okamoto; Christian Helmut Pfob; Thorsten D Pöppel; Christoph Rischpler; Sarah Schwarzenböck; Vanessa Stebner; Marcus Unterrainer; Helle D Zacho; Tobias Maurer; Christian Gratzke; Alexander Crispin; Johannes Czernin; Ken Herrmann; Matthias Eiber
Journal:  J Nucl Med       Date:  2017-04-13       Impact factor: 10.057

Review 3.  Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Authors:  Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

4.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

5.  Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.

Authors:  Matthias Eiber; Ken Herrmann; Jeremie Calais; Boris Hadaschik; Frederik L Giesel; Markus Hartenbach; Thomas Hope; Robert Reiter; Tobias Maurer; Wolfgang A Weber; Wolfgang P Fendler
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

6.  Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Sangwon Han; Sungmin Woo; Yeon Joo Kim; Chong Hyun Suh
Journal:  Eur Urol       Date:  2018-04-18       Impact factor: 20.096

7.  Image quality and semi-quantitative measurements of the Siemens Biograph Vision PET/CT: Initial experiences and comparison with Siemens Biograph mCT PET/CT.

Authors:  Joyce van Sluis; Ronald Boellaard; Ananthi Somasundaram; Paul van Snick; Ronald Borra; Rudi Dierckx; Gilles Stormezand; Andor Glaudemans; Walter Noordzij
Journal:  J Nucl Med       Date:  2019-06-28       Impact factor: 10.057

8.  68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging.

Authors:  Christoph Rischpler; Teresa I Beck; Shozo Okamoto; Anna M Schlitter; Karina Knorr; Markus Schwaiger; Jürgen Gschwend; Tobias Maurer; Philipp T Meyer; Matthias Eiber
Journal:  J Nucl Med       Date:  2018-01-25       Impact factor: 10.057

9.  Image Quality and Activity Optimization in Oncologic 18F-FDG PET Using the Digital Biograph Vision PET/CT System.

Authors:  Joyce van Sluis; Ronald Boellaard; Rudi A J O Dierckx; Gilles N Stormezand; Andor W J M Glaudemans; Walter Noordzij
Journal:  J Nucl Med       Date:  2019-10-18       Impact factor: 10.057

Review 10.  (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report.

Authors:  Isabel Rauscher; Tobias Maurer; Wolfgang P Fendler; Wieland H Sommer; Markus Schwaiger; Matthias Eiber
Journal:  Cancer Imaging       Date:  2016-06-08       Impact factor: 3.909

View more
  3 in total

Review 1.  Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology.

Authors:  David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

2.  Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system.

Authors:  Pedro Fragoso Costa; Walter Jentzen; Alissa Brahmer; Ilektra-Antonia Mavroeidi; Fadi Zarrad; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Maurizio Conti; Robert Seifert; Miriam Sraieb; Manuel Weber; David Kersting
Journal:  BMC Cancer       Date:  2022-08-18       Impact factor: 4.638

3.  New PET technologies - embracing progress and pushing the limits.

Authors:  Nicolas Aide; Charline Lasnon; Adam Kesner; Craig S Levin; Irene Buvat; Andrei Iagaru; Ken Hermann; Ramsey D Badawi; Simon R Cherry; Kevin M Bradley; Daniel R McGowan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-03       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.